REFERENCES

1. ICH HARMONISED TRIPARTITE GUIDELINE QUALITY RISK MANAGEMENT, Q9 Current step 4 version dated 9 November 2005.
2. European Medicines Agency, Quality Risk Management (ICH Q9), 31 January 2011, EMA/INS/GMP/79766/2011
3. FDA Industry Guidance: "Part 11, Electronic Records; Electronic Signatures - Scope and Application", 2003.
4. Report by WHO Expert Committee on "Specifications for Pharmaceutical Preparation", Annex 7, Application of HACCP Methodology to Pharmaceuticals, 2003.
5. PIC/S Quality Risk Management: "Implementation of ICH Q9 in the Pharmaceutical Field", 2010.
6. ISO 31010: "Risk Assessment Techniques", 2009.
7. Vesper J.L., (2006) "Risk Assessment and Risk Management in the Pharmaceutical Industry: Clear and Simple", Davis Healthcare International Publishing, LLC.
8. FDA: Pharmaceutical cGMPs for the 21st Century: "A Risk-Based Approach: Second Progress. Report and Implementation Plan", 2003.
9. FDA Guidance for Industry: "Quality Systems Approach to Pharmaceutical CGMP Regulations", (2006).
10. Guidance for Industry Q9 Quality Risk Management, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) June 2006.
11. U.S. Department of Health and Human Services Food and Drug Administration Centre for Drug Evaluation and Research (CDER) Centre for Biologics Evaluation and Research (CBER) November 2011
12. EU GMP, Annex 15: "Validation and Qualification", 2010.
13. The European Council Directive 93/42/EEC of 14 June 1993 Concerning Medical Devices.
14. FDA 21 CFR 820: "Quality System Regulation (for Devices)".

15. FDA Guidance “Inspections of Quality Systems” (Medical Devices), ORA Inspectional References.
16. Pharmaceutical Inspection Convention/Cooperation Scheme (PIC/S): "Good Practices for Computerised Systems in Regulated 'GxP' Environments".
17. PIC/S Quality Risk Management: "Implementation of ICH Q9 in the Pharmaceutical Field", 2010.
18. United States Pharmacopeia: <232> Elemental Impurities.
19. USP Chapter <467> Residual Solvents.
20. ISO 14791:2007: "Application of Risk Management to Medical Devices".
21. ISO 31000: "Risk Management" Principles and Guidelines, 2009.
22. ISO 31010: "Risk Assessment Techniques", 2009.
23. Boulanger B.(2009), A risk-based analysis of the AAPS conference report on quantitative Bioanalytical methods validation and implementation, Journal of Chromatography B, 877, 2235–2243
24. Diane B. (2008), Risk—What is it?, Toxicology Letters 180, 68–71
25. Cynthia G. McCormick, (2009), Case histories in pharmaceutical risk management, Drug and Alcohol Dependence, 105, 42–55
26. John V. (2011), Quality risk in offshore manufacturing: Evidence from the pharmaceutical industry, Journal of Operations Management 29, 737–752
27. Jeff J, (2010), A Review of Quantitative Risk–Benefit Methodologies for Assessing Drug Safety and Efficacy—Report of the ISPOR, Risk–Benefit Management Working Group, International Society for Pharmacoeconomics and outcomes Research (ISPOR), 13, 657 - 666
28. C. Agut (2011), Transfer of analytical procedures: A panel of strategies selected for risk management, with emphasis on an integrated equivalence-based comparative testing approach, Journal of Pharmaceutical and Biomedical Analysis 56, 293– 303
29. E. Smith (1996), Variability in toxic response - relevance to chemical safety and risk assessment at the global level, Environmental Toxicology and Pharmacology 2, 85-88

30. D. Blakey (2008), Regulatory aspects of genotoxicity testing: from hazard identification to risk assessment, Mutation Research/Genetic Toxicology and Environmental Mutagenesis 657, 84–90
31. Sudhanshu S. (2010), Effect of Total Quality Management on Performance of Indian Pharmaceutical Industries, Proceedings of the 2010 International Conference on Industrial Engineering and Operations Management
32. Michael H. (2006), Strategic risk management using complementary assets: Organizational capabilities and the commercialization of human genetic testing in the UK, Research Policy 35, 355–374
33. Curtis W. IV (2006), Risk identification, risk assessment, and risk management of abusable drug formulations, Drug and Alcohol Dependence 83, 68–76
34. Christine H. (2003), Risk in supply networks, Journal of Purchasing & Supply Management 9, 51–62
35. Sven O. H. (2006), Evaluating the risk decision process, Toxicology 218 100–111
36. Ioannis S A (2009), Application of Failure Mode and Effect Analysis (FMEA) and Cause and Effect Analysis in Conjunction with ISO 22000 to a Snails (Helix aspersa) Processing Plant; A Case Study, Food Science and Nutrition, 49 (7), 2009, 607-625
37. Hartmut F. Z (2011), Proposal on How To Conduct a Biopharmaceutical Process Failure Mode and Effect Analysis (FMEA) as a Risk Assessment Tool, PDA Journal of Pharmaceutical Science and Technology, 65, 5, 506-512
38. Giovanna B (2010), Clinical risk analysis with failure mode and effect analysis (FMEA) model in a dialysis unit, JNEPHROL, 23 (01), 111-118
39. Richard C. (2009), Monitoring risk: Post marketing surveillance and signal detection, Drug and Alcohol Dependence, 105S, S26–S32